Guilherme Dabus, MD
@gdabus
Followers
1K
Following
2K
Media
48
Statuses
542
interventional neuroradiologist, neuroendovascular surgeon, semi-pro guitarist, basketball-swimming-tennis weekend coach (when not on call!!!)
Joined May 2010
University of Oregon enrolled the last patient in #HEMERA 1 This concludes phase 1 trial!#stroke
@RaulNogueiraMD @DiogoHaussen @AmeerEHassan @almuftifawaz @DanielVelaMD @NguyenThanhMD @docroc99 @JoshuaAHirsch @gdabus @DrBTKatzen @dliebesk @svinsociety @AliciaCastongu2 @VladoKZg
0
14
48
Thank you #SNIS for having me presenting #HEMERA 1 data and the Propensity Score Analysis at #SNIS2025
@DrAltschul @gdabus @RaulNogueiraMD @BaptistHealthSF @DanielVelaMD @DrJessicaCampos @SNISinfo @NN_publishing @AshuPJadhav @svinsociety @SVINJournal
1
6
19
Only 1 week left until #MiamiNeuro23 where the expert faculty will share the latest treatments for neurological conditions including #stroke, subarachnoid hemorrhage, #epilepsy, #dementia, and #multiplesclerosis as well as robust discussion on the latest advancements in
0
2
5
Kudos to Dr. Guilherme Dabus (@gdabus) for recently presenting results from the SUMMIT MAX trial at @ESOstroke #ESOC2025 in Helsinki.
0
3
6
The Hi-Point reperfusion system (.088"/.070") was non-inferior and superior to the Vecta aspiration system (.074"/.071") in successful reperfusion. - High deliverability to M1 - High First Pass effect - Lower use of adjunctive devices - Similar Safety and Clinical outcomes
1
6
16
Thank you to all Investigators and their team for enrolling patients into SUMMIT MAX
0
1
9
SUMMIT MAX: A randomized trial of the super large bore HiPoint Reperfusion System versus Vecta System for aspiration thrombectomy | Stroke https://t.co/lij5qX3srV Presented this morning at #ESOC2025 with @gdabus @ajitspuri1 et al. in Helsinki
2
15
71
🌟Presented today at #ESOC2025: SUMMIT MAX: A randomized trial of the super large bore HiPoint Reperfusion System versus Vecta System for aspiration thrombectomy by @NguyenThanhMD et al. #stroke #AHAJournals @ESOstroke @gdabus
https://t.co/9MFdiXozBk
1
11
36
Congratulations to SNIS members @gdabus @HettsSteven @dgandhimd Cliff Eskey & Sudipta Roychowdhury on attaining Fellowship in @RadiologyACR! #FACR #ACR2022
1
4
13
2 of my fellows became FACR tonight. I am so unbelievably proud-literally don’t know what 2 say (which is rare) @gdabus @italolinfante @SNISinfo @MGHImaging #ohwhatanihht!!!!
7
1
62
The classics... legendary historic Neuroradiology books... #neurorad @TheASNR @SNISinfo @esmintsociety @JoshuaAHirsch @Fie0815 @docroc99 @meyerspm @CPDerdeyn @WBrinjikji
4
5
75
📘🧠 HAPPENING SOON: Don't miss today's @JNIS_BMJ Journal Club webinar at 4pm ET. JNIS Social Media Asst. Editor @rdeleacymd will sit down with authors Ricardo Hanel, MD & @_AdnanSiddiqui & discussants @gdabus & Roberta Novakovic, MD. Register today ➡️ https://t.co/KYeykpdmEk
1
1
9
We all need to do our part! Social distancing, masks, vaccine. The disease is treacherous and that’s the reality for now...@BaptistHealthSF #CovidVaccine
3
0
36
SIMI 2020 Invited professors December 3-4-5 Free registration & info: https://t.co/gXhs8AmmoS
0
4
13
Improvement in device technology is an amazing thing... 088 distal access sheath... good job @imperative_care and thanks to all companies that make our job easier and help improving patient outcome
2
6
61
Excited to be among this international team of experts set to speak at the International Symposium Of Neuroradiology later this month! @DiogoHaussen @gdabus @neurofox @VitorMendesPer1 @FBarkhof @HuismanThierry
#Neuroradiology #Neurorad #MedTwitter #MedEd #NeuroTwitter
0
3
18
Everyone should read this! Leadership is all about service, not privileges!!! Ego Is the Enemy of Good Leadership
hbr.org
The inflated ego that comes with success – the bigger salary, the nicer office, the easy laughs – often makes us feel as if we’ve found the eternal answer to being a leader. But the reality is, we...
0
1
28
The professional and personal impact of the coronavirus pandemic on US neurointerventional practices: a nationwide survey
0
8
14
Rai et al: Neuroendovascular clinical trials disruptions due to COVID-19 potential future challenges and opportunities. https://t.co/Dk0hu1sjla
0
5
11